Last reviewed · How we verify
Enbrel plus Celebrex
At a glance
| Generic name | Enbrel plus Celebrex |
|---|---|
| Also known as | celecoxib plus etanercept |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis (PHASE4)
- Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis (PHASE4)
- Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enbrel plus Celebrex CI brief — competitive landscape report
- Enbrel plus Celebrex updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI